A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday.
It’s the first known patient death with the therapy, which has been ... about its effectiveness in treating Duchenne muscular dystrophy. It’s the first gene therapy approved in the U.S ...